Yuri Deigin

Yuri Deigin is a biotech entrepreneur with over a decade of drug discovery and development experience. He is currently leading a longevity gene therapy startup dedicated to partial reprogramming. He has led several early stage pharmaceutical startups, including one developing an Alzheimer’s disease therapeutic and another developing small-molecule neuroprotectors for Alzheimer’s, Parkinson’s, and a rare pediatric disease.

Latest

######### Contributor Article Content #########
######### Card Contributor Article #########

Medicine Thunder Out of China [long_description] For the moment, the best explanation for the origins of COVID-19 seems to be that the virus escaped from the Wuhan Institute of Virology, where scientists were engaged in creating novel SARS-like chimeras and potentially supercharging their transmissibility and pathogenicity.

ISSN #2576–4403